Lumantad, Ahsen .
HRN: 26-18-31 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/06/2024
OXACILLIN 500MG (VIAL)
11/06/2024
11/13/2024
IV DRIP FOR 30 MIN
200
Q6
Skin Lesion
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes